[Molecular pathology and targeted therapy of clear cell renal cancer].

Abstract

The golden standard of care for advanced renal cell cancer (RCC) was until now the cytokine therapy with relatively low response rates. Advances of molecular genetics in RCC revealed several molecular targets such as VHL and angiogenic genotype or EGFR in the clear cell variant. Among the novel targeted agents, multiple tyrosine kinase inhibitors were proved to be clinically effective against advanced clear cell renal cancer, changing the standard of care. It is a further question how molecular diagnostics can improve these results by the detection of these targets or gene defects in individual tumors.

• Authors: József Tímár, László Kopper, István Bodrogi
• Journal: Magyar onkologia (Magy Onkol) Vol. 50 Issue 4 Pg. 309-14 ( 2006) ISSN: 0025-0244 [Print] Hungary
• Vernacular Title: A világossejtes veserák célzott terápiája és molekuláris patológiai alapjai.
• PMID: 17216004 (Publication Type: Journal Article, Review)

Chemical References

• Angiogenesis Inhibitors
• Enzyme Inhibitors
• ErbB Receptors
• Protein-Tyrosine Kinases

Topics

• Adenocarcinoma, Clear Cell (drug therapy, pathology)
• Angiogenesis Inhibitors (therapeutic use)
• Carcinoma, Renal Cell (chemistry, drug therapy, pathology)
• Enzyme Inhibitors (therapeutic use)
• ErbB Receptors (drug effects)
• Humans
• Kidney Neoplasms (chemistry, drug therapy, pathology)
• Predictive Value of Tests
• Protein-Tyrosine Kinases (antagonists & inhibitors)